Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes

• Published in: International journal of antimicrobial agents 2018-03, Vol.51 (3), p.498-502
• Main Authors: Dietl, B., Sánchez, I., Arcenillas, P., Cuchi, E., Gómez, L., González de Molina, F.J., Boix-Palop, L., Nicolás, J., Calbo, E.
• Format: Article
• Language: English
• Subjects: Ceftolozane/tazobactam; Multidrug resistance; Osteomyelitis; Pseudomonas aeruginosa; Skin and soft-tissue infection
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2017.11.003

•Extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) infections are a clinical challenge.•Ceftolozane is a new broad-spectrum cephalosporin with activity against XDR-PA.•Tazobactam broadens the spectrum to include many ESBL-producing organisms.•Ceftolozane/tazobactam (C/T) achieved clinical cure in 7 elderly patients with XDR-PA infections.•The antimicrobial spectrum, safety and efficacy make C/T an optimal treatment. Infections due to multidrug-resistant bacteria (MDR) are currently a clinical challenge, mainly in elderly patients. The antimicrobial spectrum, safety and efficacy of ceftolozane/tazobactam (C/T) make it an attractive option for the treatment of MDR bacterial infections beyond the indications approved to date. Here we report our experience with C/T in four cases of osteomyelitis and three cases of skin and soft-tissue infections due to extensively-drug-resistant Pseudomonas aeruginosa.